Arkolith/Insider Trading/TYRA/Form 4

Kaplan Gilla

DirectorTyra Biosciences, Inc. (TYRA) · full profile →Form 4 · filed Mar 27, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$528K
Net Open-Market Flow
-$528K
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 26, 2026Option exercise(M)53K$2.25$120K81K
Mar 26, 2026Disposed to issuer(D)53K$37.75$2.0M28K
Mar 25, 2026Sell(S)14K$36.97$528K28K
Mar 25, 2026Option exercise(M)14K$2.25$32K43K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 26, 2026Option exercise(M)53K—$00
Mar 25, 2026Option exercise(M)14K—$053K

Transaction Codes

M
Option exercise / conversion
D
Disposition to the issuer
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-129239) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML